Luigi Cavanna
YOU?
Author Swipe
View article: Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial
Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial Open
View article: Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early <i>ERBB2</i>-Positive Breast Cancer
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early <i>ERBB2</i>-Positive Breast Cancer Open
Importance For patients with early ERBB2 (formerly HER2 )–positive breast cancer, there is a need to identify biomarkers to guide treatment de-escalation. Objective To evaluate the association of tumor-infiltrating lymphocytes (TILs) with …
View article: Travel burden and carbon dioxide emission reductions through a model of cancer care closer to the patient
Travel burden and carbon dioxide emission reductions through a model of cancer care closer to the patient Open
Background Traveling to healthcare facilities, particularly in the case of patients requiring frequent visits and repeated treatments, such as cancer patients, is associated with substantial carbon dioxide (CO2) emissions. Moreover, travel…
View article: Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy (GARIBALDI)
Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy (GARIBALDI) Open
View article: The Fundamental Role of the Repo Market and Central Clearing
The Fundamental Role of the Repo Market and Central Clearing Open
View article: Survival analysis of the metastatic cohort of Italian Association of Medical Oncology (AIOM) GARIBALDI survey
Survival analysis of the metastatic cohort of Italian Association of Medical Oncology (AIOM) GARIBALDI survey Open
View article: Withdrawal notice to <Corrigendum to “Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study” [The Lancet Regional Health – Europe 41 (2024) 100912]>
Withdrawal notice to Open
[This retracts the article DOI: 10.1016/j.lanepe.2024.100973.].
View article: Communication in oncology between healthcare providers, patients, the scientific community, and the media: recommendations from the Italian Association of Medical Oncology (AIOM)
Communication in oncology between healthcare providers, patients, the scientific community, and the media: recommendations from the Italian Association of Medical Oncology (AIOM) Open
View article: WITHDRAWN: Corrigendum to “Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study” [The Lancet Regional Health – Europe 41 (2024) 100912]
WITHDRAWN: Corrigendum to “Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study” [The Lancet Regional Health – Europe 41 (2024) 100912] Open
View article: Autoimmune Encephalitis following Checkpoint Inhibitor Therapy in a Patient with Metastatic Melanoma in Complete Remission
Autoimmune Encephalitis following Checkpoint Inhibitor Therapy in a Patient with Metastatic Melanoma in Complete Remission Open
The use of immune checkpoint inhibitors (ICIs) in cancer is increasing. Their side effects are mainly due to the triggering of autoimmunity, which are mild or moderate and include skin rash, colitis, hepatitis, endocrine disorders, myositi…
View article: Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study
Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study Open
View article: Autoimmune Encephalitis Following Check Point Inhibitor Therapy in a Patient with Metastatic Melanoma in Complete Remission
Autoimmune Encephalitis Following Check Point Inhibitor Therapy in a Patient with Metastatic Melanoma in Complete Remission Open
A 68-year-old man with malignant metastatic melanoma in complete remission after Pembrolizumab treatment, developed 10 months after Pembrolizumab cessation due a grade 3 diarrhea, confusion, altered mental status, progressive memory loss, …
View article: FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel as First Line Treatment in Pancreatic Cancer: A Real-World Comparison
FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel as First Line Treatment in Pancreatic Cancer: A Real-World Comparison Open
Background/Aim: Advanced pancreatic cancer has a poor prognosis and a 5-year survival rate <5%; thus, treatment of patients with advanced unresectable or metastatic disease is challenging. Current guidelines recommend either gemcitabine pl…
View article: Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects
Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects Open
Purpose Optimal use of bone-modifying agents (BMAs) in patients with bone metastases from solid tumors is uncertain in some aspects: the drug choice; the planned treatment duration and long-term therapy; the prevention and management of po…
View article: Humoral Response and Safety after a Fourth Dose of the SARS-CoV-2 BNT162b2 Vaccine in Cancer Patients Undergoing Active Treatment—Results of a Prospective Observational Study
Humoral Response and Safety after a Fourth Dose of the SARS-CoV-2 BNT162b2 Vaccine in Cancer Patients Undergoing Active Treatment—Results of a Prospective Observational Study Open
Only a few studies have been carried out on the efficacy and safety of a fourth dose of the COVID-19 vaccine in patients with cancer. In this prospective observational study, we aimed to assess the serological response and safety of the fo…
View article: Commodity Markets in an Uncertain World: Geopolitical Uncertainty and Wheat Futures Prices
Commodity Markets in an Uncertain World: Geopolitical Uncertainty and Wheat Futures Prices Open
View article: Contralateral Prophylactic Mastectomy and Oophorectomy Increase the Survival in Brca-Related Breast Cancer: The Italian Mutina Study
Contralateral Prophylactic Mastectomy and Oophorectomy Increase the Survival in Brca-Related Breast Cancer: The Italian Mutina Study Open
View article: Cancer Treatment Closer to the Patient Reduces Travel Burden, Time Toxicity, and Improves Patient Satisfaction, Results of 546 Consecutive Patients in a Northern Italian District
Cancer Treatment Closer to the Patient Reduces Travel Burden, Time Toxicity, and Improves Patient Satisfaction, Results of 546 Consecutive Patients in a Northern Italian District Open
Background and Objectives: The distance to cancer facilities may cause disparities by creating barriers to oncologic diagnosis and treatment, and travel burden may cause time and financial toxicity. Materials and Methods: To relieve travel…
View article: Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours Open
View article: 1666P Non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) guideline application in real-world: Multi-Institutional based survey of adjuvant and first-line pancreatic ductal adenocarcinoma treatment in Italy (GARIBALDI)
1666P Non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) guideline application in real-world: Multi-Institutional based survey of adjuvant and first-line pancreatic ductal adenocarcinoma treatment in Italy (GARIBALDI) Open
View article: Implementation of Precision Oncology in the National Healthcare System: A Statement Proposal Endorsed by Italian Scientific Societies
Implementation of Precision Oncology in the National Healthcare System: A Statement Proposal Endorsed by Italian Scientific Societies Open
PURPOSE Precision oncology (PO) promises positive results for patients. To date, in Italy, the effort to implement PO has been made autonomously by regional health institutions in a top-down fashion. This approach is not very efficient and…
View article: Cancer treatment closer to the patient, reduces travel burden, time toxicity and improve patients satisfaction. Results on 546 consecutive patients in a North Italy district
Cancer treatment closer to the patient, reduces travel burden, time toxicity and improve patients satisfaction. Results on 546 consecutive patients in a North Italy district Open
Purpose The distance to cancer facilities may cause disparities by creating barriers to oncologic diagnosis and treatment, and travel burden may cause time and financial toxicity. Methods To relieve travel burden, a program to deliver onco…
View article: Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients Open
View article: The Impact of NUTRItional Status at First Medical Oncology Visit on Clinical Outcomes: The NUTRIONCO Study
The Impact of NUTRItional Status at First Medical Oncology Visit on Clinical Outcomes: The NUTRIONCO Study Open
Malnutrition affects up to 75% of cancer patients and results from a combination of anorexia and metabolic dysregulation. Metabolic and nutritional abnormalities in cancer patients can lead to cachexia, a multifactorial syndrome characteri…
View article: SO-27 Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO
SO-27 Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO Open
View article: Table S5 from <i>PIK3CA</i> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2<sup>+</sup> Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Table S5 from <i>PIK3CA</i> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2<sup>+</sup> Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype Open
Additional prognostic value (DFS) of TILs, PIK3CA mutation, PDCD1 expression and MYBL2 expression to integrated prognostic models.
View article: Figure S1 from <i>PIK3CA</i> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2<sup>+</sup> Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Figure S1 from <i>PIK3CA</i> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2<sup>+</sup> Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype Open
Consort diagram of ShortHER patients for the different analyses described in the present work.
View article: Figure S2 from <i>PIK3CA</i> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2<sup>+</sup> Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Figure S2 from <i>PIK3CA</i> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2<sup>+</sup> Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype Open
Pattern of PIK3CA mutations in the ShortHER trial (n=803 patients).
View article: Table S4 from <i>PIK3CA</i> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2<sup>+</sup> Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Table S4 from <i>PIK3CA</i> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2<sup>+</sup> Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype Open
Differentially expressed genes in HER2-enriched tumors according to PIK3CA mutation.
View article: Table S2 from <i>PIK3CA</i> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2<sup>+</sup> Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Table S2 from <i>PIK3CA</i> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2<sup>+</sup> Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype Open
Baseline characteristics of the patients included (PIK3CA cohort) or not (no-PIK3CA cohort) in the PIK3CA analysis.